Exchange Traded Concepts LLC Invests $148,000 in Inhibrx, Inc. (NASDAQ:INBX)

Exchange Traded Concepts LLC bought a new stake in shares of Inhibrx, Inc. (NASDAQ:INBX) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 9,608 shares of the company’s stock, valued at approximately $148,000. Exchange Traded Concepts LLC owned 0.07% of Inhibrx at the end of the most recent quarter.

Insider Buying and Selling

In other Inhibrx news, Director Jon Faiz Kayyem bought 69,686 shares of the business’s stock in a transaction that occurred on Tuesday, November 19th. The stock was purchased at an average cost of $14.23 per share, with a total value of $991,631.78. Following the completion of the acquisition, the director now owns 51,093 shares in the company, valued at $727,053.39. This trade represents a -374.80 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 22.20% of the stock is owned by company insiders.

Inhibrx Stock Up 0.2 %

INBX opened at $13.58 on Friday. The company has a fifty day moving average of $14.49 and a 200 day moving average of $14.63. Inhibrx, Inc. has a fifty-two week low of $10.80 and a fifty-two week high of $18.95.

Analyst Upgrades and Downgrades

Separately, JMP Securities reaffirmed a “market perform” rating on shares of Inhibrx in a report on Wednesday, January 22nd.

Inhibrx Company Profile

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.